Dynavax Technologies Corporation (NASDAQ:DVAX) announced that it has entered into a note purchase agreement with one or more funds of Deerfield Management Company, L.P, …
Dynavax Technologies Corporation (NASDAQ:DVAX) announced sub-group results from HBV-23, the pivotal Phase 3 trial of its investigational hepatitis B vaccine HEPLISAV-B™ [Hepatitis B Vaccine, …
Dynavax Technologies Corporation (NASDAQ:DVAX) shares have tumbled recently on the heels of last Friday’s FDA announcement of the cancellation of the November 16, 2016 …
In a research report issued this morning, Cowen Phil Nadeau reiterated an Outperform rating on shares of Dynavax Technologies Corporation (NASDAQ:DVAX), with a price target …
Dynavax Technologies Corporation (NASDAQ:DVAX) reported financial results for the first quarter endedMarch 31, 2016. The Company had $166.
Healthcare analysts give their two cents on recent updates by MannKind Corporation (NASDAQ:MNKD) and Dynavax Technologies Corporation (NASDAQ:DVAX). One analyst remains on the …
Dynavax Technologies Corporation (NASDAQ:DVAX) announced that the U.S.
Dynavax Technologies Corporation (NASDAQ:DVAX) announced results from HBV-23, a pivotal Phase 3 trial that provides head-to-head safety and immunogenicity data comparing its investigational adult …
Dynavax Technologies Corporation (NASDAQ:DVAX) reported financial results for the fourth quarter and year ended December 31, 2015. The Company had $196.
